8-K: Ginkgo Bioworks Reports Mixed Results for 2023, Focuses on Biopharma Growth and Platform Efficiency

Ginkgo Bioworks announced its fourth quarter and full year 2023 financial results, highlighting growth in cell engineering services but a decline in overall revenue due to the transition of its biosecurity business.

Summary

• Ginkgo Bioworks reported a total revenue of $251 million for 2023, a decrease of 47% compared to the previous year, primarily due to a shift in the biosecurity business model away from K-12 testing.
• Cell Engineering services revenue grew by 31% to $139 million in 2023, with 78 new cell programs added, representing a 32% increase year-over-year.
• The Biosecurity segment generated $108 million in revenue, a 68% decrease from the prior year, as it transitioned to a recurring model focused on global reach and multiple pathogens.
• The company's fourth quarter revenue was $35 million, a 65% decrease compared to the same period in 2022, mainly due to the expected reduction in K-12 testing and the absence of downstream value share from equity milestones.
• Ginkgo's full year loss from operations was $(864) million, which included $235 million in stock-based compensation expense, compared to a loss of $(2.2) billion in the prior year.
• The company ended the year with a cash balance of nearly $950 million, providing a multi-year runway as it aims for profitability.
• Ginkgo expects to add 100-120 new Cell Programs in 2024 and anticipates total revenue of $215-$235 million, with Cell Engineering services revenue projected at $165-185 million.

Sentiment

Score: 5

Explanation: The document presents a mixed picture with strong growth in cell engineering offset by significant revenue declines and losses. The company's strategic moves and cash position are positive, but the overall financial performance is concerning.

Positives

• Cell Engineering services revenue showed strong growth, increasing by 31% in 2023.
• The addition of 78 new Cell Engineering Programs indicates strong market demand and growth potential.
• Ginkgo's cash balance of nearly $950 million provides a solid financial foundation for future operations.
• The launch of the Technology Network and strategic acquisitions are expected to enhance Ginkgo's capabilities and offerings.
• The company is seeing strong momentum in biopharma, which represents its largest untapped market.
• Ginkgo is expanding its global bioradar network, now in 14 countries and 10 airports.

Negatives

• Total revenue decreased by 47% in 2023, primarily due to the transition in the Biosecurity segment.
• Fourth quarter revenue declined significantly by 65% compared to the same period in 2022.
• The company reported a substantial loss from operations of $(864) million for the full year 2023.
• Adjusted EBITDA for the full year 2023 was $(355) million, down from $(173) million in the prior year.
• Biosecurity revenue decreased by 68% in 2023, reflecting the shift away from K-12 testing.

Risks

• The transition of the Biosecurity business model may continue to impact revenue in the short term.
• The company's reliance on downstream value share revenue introduces uncertainty in future financial performance.
• The company faces risks related to the development and commercialization success of its customers.
• The company's stock price may be volatile due to various factors, including changes in the competitive landscape and regulations.
• There is uncertainty regarding the demand for passive monitoring programs and biosecurity services.

Future Outlook

Ginkgo expects to add 100-120 new Cell Programs in 2024, with total revenue projected at $215-$235 million and Cell Engineering services revenue at $165-185 million. Biosecurity revenue is expected to be at least $50 million.

Management Comments

• Jason Kelly, co-founder and CEO of Ginkgo, stated that 2023 was a breakout year for Ginkgo and that they are working to build a durable platform that fundamentally transforms R&D in biotech.
• Jason Kelly also expressed pleasure with the growth in biopharma and the building of an ecosystem around Ginkgo.

Industry Context

Ginkgo's focus on cell programming and biosecurity aligns with the growing demand for synthetic biology solutions in various sectors, including pharmaceuticals, agriculture, and public health. The company's expansion into biopharma and its technology network reflect a broader trend of collaboration and integration in the biotech industry.

Comparison to Industry Standards

• Ginkgo's 31% growth in Cell Engineering services revenue is a positive sign, but the overall revenue decline of 47% is significant and needs to be compared to other synthetic biology companies.
• Companies like Amyris and Zymergen, which have faced financial difficulties, highlight the challenges in scaling synthetic biology platforms. Ginkgo's focus on biopharma and its technology network could be a differentiator.
• The biosecurity segment's transition to a recurring model is a strategic move, but its impact on revenue needs to be monitored against competitors in the biosecurity space.
• Ginkgo's cash position of nearly $950 million is strong compared to many other biotech startups, providing a buffer for future growth and development.

Stakeholder Impact

• Shareholders may be concerned about the significant revenue decline and losses, but the company's cash position and strategic initiatives could provide long-term value.
• Employees may be impacted by the company's restructuring and cost-cutting measures.
• Customers may benefit from the expanded capabilities and integrated technologies offered by Ginkgo.
• Suppliers and creditors may be affected by the company's financial performance and future outlook.

Next Steps

• Ginkgo will host a videoconference on February 29, 2024, to discuss the results and outlook.
• The company plans to continue expanding its Technology Network and integrating new technologies.
• Ginkgo will focus on growing its biopharma business and expanding its global bioradar network.
• The company will work towards achieving profitability and improving platform efficiency.

Key Dates

Keywords

Cell Engineering, Biosecurity, Synthetic Biology, Biopharma, Revenue, EBITDA, Financial Results, Technology Network, Downstream Value Share, Ginkgo Bioworks